Chronic lymphocytic leukaemia

10 trials 5 recruiting MedDRA PT
10 Registered trials
5 Recruiting
6 Unique sponsors
9 Unique IMPs
5 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 7
J Anti-infectives (ATC J) 1
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
BTK inhibitor 3 substances
Unknown / small molecule 2 substances
BCL-2 inhibitor 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Immunoglobulin 1 substance
CAR-T cell therapy 1 substance
Phase III: 4 Phase II: 3 Phase I/II: 1 Phase I: 1 Phase I (First in Human): 1

Filter these 10 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 10 trials

Phase III

4 trials
  • AstraZeneca AB Commercial
    ACALABRUTINIB; OBINUTUZUMAB; VENETOCLAX
    2023-505866-27-00 5 countries 2022 n=387 Orphan
    Ended
  • Grifols Therapeutics LLC Commercial
    HUMAN NORMAL IMMUNOGLOBULIN
    2022-502193-16-00 5 countries 2023 n=94
    Recruiting
  • University Of Cologne Academic
    IBRUTINIB; OBINUTUZUMAB; VENETOCLAX
    2022-500439-35-00 11 countries 2021 n=841
    Ended
  • University Of Cologne Academic
    OBINUTUZUMAB; VENETOCLAX
    2023-510294-34-00 14 countries 2025 n=746
    Recruiting

Phase II

3 trials
  • Janssen - Cilag International Commercial
    IBRUTINIB; VENETOCLAX
    2023-504044-34-00 6 countries 2024 n=213
    Recruiting
  • University Of Cologne Academic
    OBINUTUZUMAB; VENETOCLAX; ZANUBRUTINIB
    2022-502201-16-00 1 country 2020 n=42
    Ended
  • University Of Cologne Academic
    ACALABRUTINIB
    2023-507002-14-00 2 countries 2021 n=53
    Ended

Phase I/II

1 trial
  • AstraZeneca AB Commercial
    ACALABRUTINIB; HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST CD3 AND CD19; SUROVATAMIG
    2024-515034-33-00 5 countries 2025 n=200
    Recruiting

Phase I

1 trial
  • Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic
    IMP not specified
    2023-507213-97-00 1 country 2024 n=52
    Recruiting

Phase I (First in Human)

1 trial
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2023-507062-34-00 5 countries 2020 n=142
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
University Of Cologne Academic 4 Phase II, Phase III 1
AstraZeneca AB Commercial 2 Phase III, Phase I/II 1
Janssen - Cilag International Commercial 1 Phase II 1
Grifols Therapeutics LLC Commercial 1 Phase III 1
Novartis Pharma AG Commercial 1 Phase I (First in Human) 0
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic 1 Phase I 1
New trials by year
2020
2
2021
2
2022
1
2023
1
2024
2
2025
2
← All indication landscapes